Publicacions en què col·labora amb Izaskun Buendía Abaitua (13)

2020

  1. Antioxidant, anti-inflammatory and neuroprotective profiles of novel 1,4-dihydropyridine derivatives for the treatment of alzheimer’s disease

    Antioxidants, Vol. 9, Núm. 8, pp. 1-20

  2. Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization

    Pharmacological Research, Vol. 152

2019

  1. Pharmacological doses of melatonin impede cognitive decline in tau-related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux

    Journal of Pineal Research, Vol. 67, Núm. 1

2017

  1. Addition to "ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia"

    ACS chemical neuroscience, Vol. 8, Núm. 1, pp. 210

  2. Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease

    Scientific Reports, Vol. 7

  3. ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia

    ACS Chemical Neuroscience, Vol. 8, Núm. 1, pp. 67-81

  4. Inclusion complex of ITH12674 with 2-hydroxypropyl-β-cyclodextrin: Preparation, physical characterization and pharmacological effect

    Carbohydrate Polymers, Vol. 157, pp. 94-104

  5. Novel multitarget hybrid compounds for the treatment of alzheimer’s disease

    Current Topics in Medicinal Chemistry, Vol. 17, Núm. 9, pp. 1027-1043

  6. Novel sulfoglycolipid IG20 causes neuroprotection by activating the phase II antioxidant response in rat hippocampal slices

    Neuropharmacology, Vol. 116, pp. 110-121

2016

  1. Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases

    Pharmacology and Therapeutics, Vol. 157, pp. 84-104

  2. The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators

    Journal of Medicinal Chemistry, Vol. 59, Núm. 21, pp. 9967-9973

2015

  1. Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models

    Neuropharmacology, Vol. 99, pp. 187-195

  2. New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection

    Future Medicinal Chemistry, Vol. 7, Núm. 15, pp. 1961-1969